This phase I trial is testing a cancer drug that works by switching on genes to stop cancer growth, to see if it is a suitable treatment for children whose brain cancer has not responded to, or has gotten worse on, prior treatment.
This trial is treating patients with brain cancer.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
- You have had treatment, but your cancer has come back.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
- You have previously been treated (or are currently being treated) on a clinical trial.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
Phase I/Ib Trial of Combined 5'Azacitidine and Carboplatin for Recurrent/Refractory Pediatric Brain and Solid Tumors
Other Non-Commercial Sponsor
The Hospital for Sick Children
This is a dose escalation and expansion trial. In the dose escalation phase of the trial, eligible patients will receive 75mg/m2/day 5'azacytidine on Days 1-7. This will be followed by escalating doses of carboplatin on Day 14, using a rolling 6 design. In this phase of the trial, carboplatin will be dosed initially at AUC 4. For dose level -1 the dose of 5'azacytidine will be reduced to to 50mg/m2/day.
The dose expansion phase will be split into two arms according to whether eligible patients have a posterior fossa- or supratentorial- ependymoma. In both arms, patients will receive 5'azacytidine (on days 1-7) and carboplatin (on day 14) at the maximum tolerated dose achieved in the dose escalation phase.
Recruiting Hospitals Read More